
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
A. 510(k) Number:
k122197
B. Purpose for Submission:
Addition of 6 new recombinant allergens and 4 purified native allergens to a cleared device
C. Measurand:
Ten new allergen-specific IgE analytes: e101, rCan f 1 (Dog); e102, rCan f 2 (Dog); e221,
nCan f 3 (Dog serum albumin); e226, rCan f 5 (Dog); f353, rGly m 4 PR-10 (Soy); f431,
nGly m 5 Beta-conglycinin (Soy); f432, nGly m 6 Glycinin (Soy); t224, rOle e 1 (Olive);
t227, nOle e 7 LTP (Olive); t240 rOle e 9 (Olive)
D. Type of Test:
Fluoroenzymeimmunoassay, Quantitative
E. Applicant:
Phadia AB
F. Proprietary and Established Names:
ImmunoCAP Specific IgE
ImmunoCAP Allergen e101, Allergen Component rCan f 1, Dog
ImmunoCAP Allergen e102, Allergen Component rCan f 2, Dog
ImmunoCAP Allergen e221, Allergen component nCan f 3, Dog serum albumin
ImmunoCAP Allergen e226, Allergen component rCan f 5, Dog
ImmunoCAP Allergen f353, Allergen component rGly m 4 PR-10, Soy
ImmunoCAP Allergen f431, Allergen component nGly m 5 Beta-conglycinin, Soy
ImmunoCAP Allergen f432, Allergen component nGly m 6 Glycinin, Soy
ImmunoCAP Allergen t224, Allergen component rOle e 1, Olive
ImmunoCAP Allergen t227, Allergen component nOle e 7 LTP, Olive
ImmunoCAP Allergen t240, Allergen component rOle e 9, Olive
G. Regulatory Information:
1. Regulation section:
21 CFR §866.5750, Radioallergosorbent (RAST) immunological test system
2. Classification:
Class II
3. Product code:
DHB - System, Test, Radioallergosorbent (RAST), Immunological
4. Panel:
Immunology (82)
1

--- Page 2 ---
H. Intended Use:
1. Intended use(s):
ImmunoCAP Specific IgE is an in vitro quantitative assay for the measurement of
allergen specific IgE in human serum or plasma (EDTA or Na-Heparin). ImmunoCAP
Specific IgE is to be used with instruments Phadia 100, Phadia 250, Phadia 1000, Phadia
2500 and Phadia 5000. It is intended for in vitro diagnostic use as an aid in the clinical
diagnosis of IgE mediated allergic disorders in conjunction with other clinical findings,
and is to be used in clinical laboratories.
2. Indication(s) for use:
Same as Intended use
3. Special conditions for use statement(s):
For prescription use only
4. Special instrument requirements:
Phadia 100, Phadia 250, Phadia 1000, Phadia 2500 and Phadia 5000
I. Device Description:
The ImmunoCAP system is a fully integrated and automated system for the determination of
specific IgE in human blood serum or plasma (EDTA or Na-Heparin) sample. It is
comprised of general, test and method specific reagents for Phadia 100, Phadia 250, Phadia
1000, Phadia 2500 and Phadia 5000 test system modules, as well as instrument and data
management software.
The general ImmunoCAP reagents include ImmunoCAP Specific IgE Conjugate,
ImmunoCAP Specific IgE Curve Control, ImmunoCAP Specific IgE Calibrators, Specific
IgE anti-IgE ImmunoCAP, Allergen ImmunoCAP carriers, ImmunoCAP development
solution and stop solution. The method specific reagents consist of individual purified
allergen (native or recombinant) covalently coupled to a support in a plastic housing.
J. Substantial Equivalence Information:
1. Predicate device name(s) and Predicate 510(k) number(s):
UniCAP® Specific IgE Assay and UniCAP® Specific IgE Conjugate 100 and 400
(k051218)
UniCAP Specific IgE Assay (k962274)
2. Comparison with predicate:
Similarities
Item Device Predicate
Intended Use An in vitro quantitative assay for Same
the measurement of allergen
specific IgE in human serum or
plasma. It is intended for in vitro
diagnostic use as an aid in the
2

[Table 1 on page 2]
Similarities								
	Item			Device			Predicate	
Intended Use			An in vitro quantitative assay for
the measurement of allergen
specific IgE in human serum or
plasma. It is intended for in vitro
diagnostic use as an aid in the			Same		

--- Page 3 ---
Similarities
Item Device Predicate
clinical diagnosis of IgE
mediated allergic disorders in
conjunction with other clinical
findings and to be used in clinical
laboratories.
Assay type Quantitative Same
Basic principle Fluoroenzymeimmunoassay Same
Antibody β-Galactosidase-anti-human IgE Same
(mouse monoclonal antibody) for
all ImmunoCAP
Specimen type Serum and plasma (EDTA and Same
Na Heparin
Sample volume 40 μL Same
Number of calibrators Six Same
Process time Phadia 100: 2 hrs 30 min. Same
Phadia 250, Phadia 1000, Phadia
2500 and Phadia 5000: 1 hour 45
minutes from entering the first
sample.
Incubation temperature 37oC - for all Phadia instruments Same
Differences
Item Device Predicate
Form of allergens Recombinant proteins and Purified native
purified whole native proteins allergens
Allergens Individual recombinant proteins: Not included
e 101, rCan f 1 (Dog); e102,
rCan f 2 (Dog); e226, rCan f 5
(Dog); f353, rGly m 4 PR-10
(Soy); t224, rOle e 1 (Olive);
tt240, rOle e 9 (Olive)
Whole allergens comprising
multiple proteins from purified
native allergen source: e221,
nCan f 3 (Dog serum albumin);
f431, nGly m 5 Beta-conglycinin
(Soy); f432, nGly m 6 Glycinin
(Soy); t227, nOle e 7 LTP
(Olive)
Sample matrix Serum and plasma (EDTA or Serum and plasma
sodium heparin) (sodium heparin)
Laboratory settings Clinical laboratories Clinical laboratories
and physician office
3

[Table 1 on page 3]
Similarities								
	Item			Device			Predicate	
			clinical diagnosis of IgE
mediated allergic disorders in
conjunction with other clinical
findings and to be used in clinical
laboratories.					
Assay type			Quantitative			Same		
Basic principle			Fluoroenzymeimmunoassay			Same		
Antibody			β-Galactosidase-anti-human IgE
(mouse monoclonal antibody) for
all ImmunoCAP			Same		
Specimen type			Serum and plasma (EDTA and
Na Heparin			Same		
Sample volume			40 μL			Same		
Number of calibrators			Six			Same		
Process time			Phadia 100: 2 hrs 30 min.
Phadia 250, Phadia 1000, Phadia
2500 and Phadia 5000: 1 hour 45
minutes from entering the first
sample.			Same		
Incubation temperature			37oC - for all Phadia instruments			Same		

[Table 2 on page 3]
Differences								
	Item			Device			Predicate	
Form of allergens			Recombinant proteins and
purified whole native proteins			Purified native
allergens		
Allergens			Individual recombinant proteins:
e 101, rCan f 1 (Dog); e102,
rCan f 2 (Dog); e226, rCan f 5
(Dog); f353, rGly m 4 PR-10
(Soy); t224, rOle e 1 (Olive);
tt240, rOle e 9 (Olive)
Whole allergens comprising
multiple proteins from purified
native allergen source: e221,
nCan f 3 (Dog serum albumin);
f431, nGly m 5 Beta-conglycinin
(Soy); f432, nGly m 6 Glycinin
(Soy); t227, nOle e 7 LTP
(Olive)			Not included		
Sample matrix			Serum and plasma (EDTA or
sodium heparin)			Serum and plasma
(sodium heparin)		
Laboratory settings			Clinical laboratories			Clinical laboratories
and physician office		

--- Page 4 ---
Differences
Item Device Predicate
laboratories.
Instruments Phadia 100, Phadia 250, Phadia UniCAP 100
1000, Phadia 2500 and Phadia
5000
Built-in Software Phadia 100: 2.34 Not available
versions Phadia 250: 2.20
Phadia 1000: 2.30
Phadia 2500: 1.30
Phadia 5000: 1.30
Phadia Information Data
Manager (IDM): 5.34
K. Standard/Guidance Document Referenced (if applicable):
CLSI EP5-A2: Evaluation of Precision Performance of Quantitative Measurement Methods;
Approved Guideline – Second Edition.
CLSI EP17-A: Protocols for Determination of Limits of Detection and Limits of
Quantitation; Approved Guideline.
CLSI I/LA20-A2: Analytical Performance Characteristics and Clinical Utility of
Immunological Assays for Human Immunoglobulin E (IgE) Antibodies and Defined Allergy
Specificities; Approved Guidelines – Second Edition.
CEN 13640: 2002 Stability Testing of in vitro Diagnostic Reagents
L. Test Principle:
The allergen of interest, covalently coupled to ImmunoCAP solid phase, reacts with the
specific IgE in the patient sample. After washing away non-specific IgE, enzyme-labeled
anti-IgE antibodies are added to form a complex. After incubation, unbound enzyme-anti-
IgE is washed away and the bound complex is then incubated with a developing agent. After
stopping the reaction, the fluorescence of the eluate is measured. The higher the response
value, the more specific IgE is present in the specimen. To evaluate the test results, the
responses for the patient samples are transformed to concentrations with the use of a
calibration curve.
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
i) Within-Lot imprecision:
Imprecision of the individual allergen components was evaluated by using two
positive plasma samples, including a low range sample (0.35 ± 25%) and a high
range sample (≥0.7 kU /L). Each sample was tested in 4 replicates in 1 assay run
A
per day for a total of 20 operating days (a total of 80 replicates per sample). The
assay was performed according to the ImmunoCAP Specific IgE Directions for
4

[Table 1 on page 4]
Differences								
	Item			Device			Predicate	
						laboratories.		
Instruments			Phadia 100, Phadia 250, Phadia
1000, Phadia 2500 and Phadia
5000			UniCAP 100		
Built-in Software
versions			Phadia 100: 2.34
Phadia 250: 2.20
Phadia 1000: 2.30
Phadia 2500: 1.30
Phadia 5000: 1.30
Phadia Information Data
Manager (IDM): 5.34			Not available		

--- Page 5 ---
Use using Phadia 250. Between-day and within-run coefficients of variance
(%CV) were calculated for each component and each sample separately. Results
of CV% values for individual allergen components are shown below:
Number CV% CV%
of Mean Between Within CV%
Allergen component Sample tests (kU /l) Run Run Total
e101, rCan f 1 46441 80 2.33 3.11 2.47 3.97
(Dog) 62849 80 0.36 4.36 2.10 4.84
e102, rCan f 2 29709 80 2.25 3.50 4.05 5.35
(Dog) 62850 80 0.37 4.36 2.77 5.16
e221, nCan f 3 37678 80 2.67 3.29 3.58 4.86
Dog serum albumin 62968 80 0.39 4.42 2.82 5.25
e226, rCan f 5 58563 80 1.70 3.81 3.06 4.89
(Dog) 62847 80 0.35 3.86 2.57 4.64
f353, rGly m 4 43293 80 2.65 3.41 3.08 4.60
PR-10 (Soy) 62972 80 0.37 4.55 2.94 5.42
f431, nGly m 5 b- 35585 80 2.71 3.58 2.66 4.45
conglycinin (Soy) 62974 80 0.38 5.17 3.90 6.48
f432, nGly m 6 27640 80 2.20 4.11 4.75 6.28
Glycinin (Soy) 62969 80 0.35 4.09 2.22 4.65
44343 80 1.99 4.60 2.55 5.26
t224, rOle e 1 (Olive)
62971 80 0.33 4.68 2.22 5.18
t227, nOle e 7 LTP 34243 80 4.58 4.07 3.66 5.47
(Olive) 62973 80 0.38 4.96 2.55 5.58
19957 80 1.68 4.59 4.12 6.16
t240, rOle e 9 (Olive)
62975 80 0.39 4.37 2.19 4.89
Results of pooled CV% values for individual allergens:
Number CV% CV%
of samples Between Within CV%
Test n run run Total
e101 2 3.78 2.29 4.42
e102 2 3.95 3.47 5.26
e221 2 3.90 3.22 5.06
e226 2 3.84 2.82 4.76
f353 2 4.02 3.01 5.03
f431 2 4.45 3.34 5.56
f432 2 4.10 3.71 5.53
t224 2 4.64 2.39 5.22
t227 2 4.53 3.15 5.52
5

[Table 1 on page 5]
		Number		CV%	CV%	
		of	Mean	Between	Within	CV%
Allergen component	Sample	tests	(kU /l)	Run	Run	Total
e101, rCan f 1
(Dog)	46441	80	2.33	3.11	2.47	3.97
	62849	80	0.36	4.36	2.10	4.84
e102, rCan f 2
(Dog)	29709	80	2.25	3.50	4.05	5.35
	62850	80	0.37	4.36	2.77	5.16
e221, nCan f 3
Dog serum albumin	37678	80	2.67	3.29	3.58	4.86
	62968	80	0.39	4.42	2.82	5.25
e226, rCan f 5
(Dog)	58563	80	1.70	3.81	3.06	4.89
	62847	80	0.35	3.86	2.57	4.64
f353, rGly m 4
PR-10 (Soy)	43293	80	2.65	3.41	3.08	4.60
	62972	80	0.37	4.55	2.94	5.42
f431, nGly m 5 b-
conglycinin (Soy)	35585	80	2.71	3.58	2.66	4.45
	62974	80	0.38	5.17	3.90	6.48
f432, nGly m 6
Glycinin (Soy)	27640	80	2.20	4.11	4.75	6.28
	62969	80	0.35	4.09	2.22	4.65
t224, rOle e 1 (Olive)	44343	80	1.99	4.60	2.55	5.26
	62971	80	0.33	4.68	2.22	5.18
t227, nOle e 7 LTP
(Olive)	34243	80	4.58	4.07	3.66	5.47
	62973	80	0.38	4.96	2.55	5.58
t240, rOle e 9 (Olive)	19957	80	1.68	4.59	4.12	6.16
	62975	80	0.39	4.37	2.19	4.89

[Table 2 on page 5]
	Number
of samples			
		CV%	CV%	
		Between	Within	CV%
Test	n	run	run	Total
e101	2	3.78	2.29	4.42
e102	2	3.95	3.47	5.26
e221	2	3.90	3.22	5.06
e226	2	3.84	2.82	4.76
f353	2	4.02	3.01	5.03
f431	2	4.45	3.34	5.56
f432	2	4.10	3.71	5.53
t224	2	4.64	2.39	5.22
t227	2	4.53	3.15	5.52

--- Page 6 ---
t240 2 4.48 3.30 5.56
ii) Lot-to-lot imprecision:
For each allergen, three different ImmunoCAP Allergen Component lots were
tested using two positive plasma samples (0.35 ± 25% and ≥0.7 kU /L) and one
A
negative plasma sample (< 0.1 kU /L). For each lot the samples were tested in 12
A
replicates in one assay run. Each lot represented a different preparation of the
allergen from routine production. The assay was performed according to the
ImmunoCAP Specific IgE, Directions for Use using Phadia 250. Mean
concentration values, %CV and concentration quotients between lots were
calculated for the positive samples.
Positive 1 Positive 2 Negative Concentration Quotient
Mean CV Mean CV Mean Positive Positive
Lot (kU /L) (%) (kU /L) (%) (kU /L) 1 2
A A A
ImmunoCAP Allergen, e101, rCan f 1, (Dog)
1 2.45 1.9 0.37 1.8 <0.1 lot1/lot2 1.04 1.05
2 2.36 2.6 0.35 1.7 <0.1 lot1/lot3 1.13 1.12
3 2.17 5.5 0.33 3.6 <0.1 lot2/lot3 1.09 1.07
ImmunoCAP Allergen, e102, rCan f 2, (Dog)
1 2.56 2.0 0.46 2.4 <0.1 lot1/lot2 1.04 1.07
2 2.47 1.8 0.43 1.8 <0.1 lot1/lot3 1.10 1.22
3 2.33 5.3 0.37 1.6 <0.1 lot2/lot3 1.06 1.14
ImmunoCAP Allergen, e221, nCan f 3 (Dog serum albumin)
1 2.64 1.3 0.38 1.9 <0.1 lot1/lot2 0.91 0.92
2 2.90 2.1 0.41 1.3 <0.1 lot1/lot3 1.00 1.00
3 2.65 1.6 0.38 2.2 <0.1 lot2/lot3 1.09 1.09
ImmunoCAP Allergen, e226, rCan f 5 (Dog)
1 1.75 2.6 0.37 3.3 <0.1 lot1/lot2 0.94 0.94
2 1.85 1.1 0.39 1.4 <0.1 lot1/lot3 0.92 0.94
3 1.90 3.5 0.39 3.4 <0.1 lot2/lot3 0.97 1.01
ImmunoCAP Allergen, f353, rGly m 4 PR-10 (Soy)
1 2.51 2.9 0.35 2.5 <0.1 lot1/lot2 1.00 0.99
2 2.52 2.5 0.35 2.7 <0.1 lot1/lot3 0.99 0.97
3 2.53 3.7 0.36 2.0 <0.1 lot2/lot3 1.00 0.98
ImmunoCAP Allergen, f431, nGly m 5 Beta-conglycinin (Soy)
1 2.72 2.7 0.36 1.9 <0.1 lot1/lot2 0.99 0.98
2 2.75 2.9 0.37 6.2 <0.1 lot1/lot3 1.03 0.94
3 2.65 1.7 0.38 1.9 <0.1 lot2/lot3 1.04 0.95
ImmunoCAP Allergen, f432, nGly m 6 Glycinin (Soy)
1 2.23 1.8 0.37 1.9 <0.1 lot1/lot2 0.99 0.99
6

[Table 1 on page 6]
t240	2	4.48	3.30	5.56

[Table 2 on page 6]
	Positive 1		Positive 2		Negative	Concentration Quotient		
	Mean	CV	Mean	CV	Mean		Positive	Positive
Lot	(kU /L)
A	(%)	(kU /L)
A	(%)	(kU /L)
A		1	2
ImmunoCAP Allergen, e101, rCan f 1, (Dog)								
1	2.45	1.9	0.37	1.8	<0.1	lot1/lot2	1.04	1.05
2	2.36	2.6	0.35	1.7	<0.1	lot1/lot3	1.13	1.12
3	2.17	5.5	0.33	3.6	<0.1	lot2/lot3	1.09	1.07
ImmunoCAP Allergen, e102, rCan f 2, (Dog)								
1	2.56	2.0	0.46	2.4	<0.1	lot1/lot2	1.04	1.07
2	2.47	1.8	0.43	1.8	<0.1	lot1/lot3	1.10	1.22
3	2.33	5.3	0.37	1.6	<0.1	lot2/lot3	1.06	1.14
ImmunoCAP Allergen, e221, nCan f 3 (Dog serum albumin)								
1	2.64	1.3	0.38	1.9	<0.1	lot1/lot2	0.91	0.92
2	2.90	2.1	0.41	1.3	<0.1	lot1/lot3	1.00	1.00
3	2.65	1.6	0.38	2.2	<0.1	lot2/lot3	1.09	1.09
ImmunoCAP Allergen, e226, rCan f 5 (Dog)								
1	1.75	2.6	0.37	3.3	<0.1	lot1/lot2	0.94	0.94
2	1.85	1.1	0.39	1.4	<0.1	lot1/lot3	0.92	0.94
3	1.90	3.5	0.39	3.4	<0.1	lot2/lot3	0.97	1.01
ImmunoCAP Allergen, f353, rGly m 4 PR-10 (Soy)								
1	2.51	2.9	0.35	2.5	<0.1	lot1/lot2	1.00	0.99
2	2.52	2.5	0.35	2.7	<0.1	lot1/lot3	0.99	0.97
3	2.53	3.7	0.36	2.0	<0.1	lot2/lot3	1.00	0.98
								
ImmunoCAP Allergen, f431, nGly m 5 Beta-conglycinin (Soy)								
1	2.72	2.7	0.36	1.9	<0.1	lot1/lot2	0.99	0.98
2	2.75	2.9	0.37	6.2	<0.1	lot1/lot3	1.03	0.94
3	2.65	1.7	0.38	1.9	<0.1	lot2/lot3	1.04	0.95
ImmunoCAP Allergen, f432, nGly m 6 Glycinin (Soy)								
1	2.23	1.8	0.37	1.9	<0.1	lot1/lot2	0.99	0.99

--- Page 7 ---
Positive 1 Positive 2 Negative Concentration Quotient
Mean CV Mean CV Mean Positive Positive
Lot (kU /L) (%) (kU /L) (%) (kU /L) 1 2
A A A
2 2.26 4.9 0.37 1.8 <0.1 lot1/lot3 1.09 1.00
3 2.06 5.1 0.37 3.1 <0.1 lot2/lot3 1.10 1.02
ImmunoCAP Allergen, t224, rOle e 1 (Olive)
1 0.31 2.2 1.43 1.7 <0.1 lot1/lot2 1.00 1.02
2 0.31 2.7 1.40 2.6 <0.1 lot1/lot3 1.00 1.01
3 0.31 2.9 1.41 2.5 <0.1 lot2/lot3 1.00 1.00
ImmunoCAP Allergen, t227, nOle e 7 LTP (Olive)
1 0.33 1.5 1.00 1.7 <0.1 lot1/lot2 0.89 0.83
2 0.37 2.4 1.21 2.6 <0.1 lot1/lot3 0.87 0.81
3 0.38 2.4 1.24 2.5 <0.1 lot2/lot3 0.98 0.98
ImmunoCAP Allergen, t240, rOle e 9 (Olive)
1 0.32 4.9 1.05 1.7 <0.1 lot1/lot2 1.03 0.95
2 0.31 8.2 1.10 1.7 <0.1 lot1/lot3 0.95 0.96
3 0.34 10.3 1.09 2.6 <0.1 lot2/lot3 0.92 1.01
b. Linearity/assay reportable range:
The linearity of the 10 individual allergens was assessed following the CLSI I/LA20-
A2 guidelines. For each allergen component, three positive plasma samples were
each diluted in negative plasma generating at least five 2-fold consecutive dilutions.
Undiluted and diluted samples were tested in four replicates in one assay run. The
assay was performed according to the ImmunoCAP Specific IgE, Directions for Use
using instrument Phadia 250. For each product one lot of ImmunoCAP Allergen
Component was used. ImmunoCAP Specific Total IgE working range is LoD to100
kU /L.
A
For each allergen, results of the replicates from all three samples were pooled and
analyzed for linearity. Regression statistics for each allergen comparing the observed
results to expected results are presented below:
Highest
Allergen Regression 95% CI 95% CI concentration
Component Equation r2 Slope Intercept tested (kU /L)
A
e101 y=0.99x+0.01 1.00 0.98-1.00 0.00-0.02 74.1
e102 y=1.01x-0.01 1.00 1.01-1.02 -0.02-(-0.01) 36.5
e221 y=0.99x 1.00 0.98-1.00 -0.01-0.01 77.6
e226 y=1.04x-0.10 1.00 1.03-1.05 -0.01-(-0.09) 92.7
f353 y=1.01x 1.00 1.00-1.01 -0.01-0.00 77.7
f431 y=0.98x+0.03 1.00 0.97-0.99 0.03-0.04 26.4
f432 y=0.98x+0.05 1.00 0.97-0.99 0.04-0.06 82.0
t224 y=0.99x+0.04 1.00 0.98-1.00 0.04-0.05 74.6
7

[Table 1 on page 7]
	Positive 1		Positive 2		Negative	Concentration Quotient		
	Mean	CV	Mean	CV	Mean		Positive	Positive
Lot	(kU /L)
A	(%)	(kU /L)
A	(%)	(kU /L)
A		1	2
2	2.26	4.9	0.37	1.8	<0.1	lot1/lot3	1.09	1.00
3	2.06	5.1	0.37	3.1	<0.1	lot2/lot3	1.10	1.02
ImmunoCAP Allergen, t224, rOle e 1 (Olive)								
1	0.31	2.2	1.43	1.7	<0.1	lot1/lot2	1.00	1.02
2	0.31	2.7	1.40	2.6	<0.1	lot1/lot3	1.00	1.01
3	0.31	2.9	1.41	2.5	<0.1	lot2/lot3	1.00	1.00
ImmunoCAP Allergen, t227, nOle e 7 LTP (Olive)								
1	0.33	1.5	1.00	1.7	<0.1	lot1/lot2	0.89	0.83
2	0.37	2.4	1.21	2.6	<0.1	lot1/lot3	0.87	0.81
3	0.38	2.4	1.24	2.5	<0.1	lot2/lot3	0.98	0.98
ImmunoCAP Allergen, t240, rOle e 9 (Olive)								
1	0.32	4.9	1.05	1.7	<0.1	lot1/lot2	1.03	0.95
2	0.31	8.2	1.10	1.7	<0.1	lot1/lot3	0.95	0.96
3	0.34	10.3	1.09	2.6	<0.1	lot2/lot3	0.92	1.01

[Table 2 on page 7]
					
					Highest
Allergen	Regression		95% CI	95% CI	concentration
Component	Equation	r2	Slope	Intercept	tested (kU /L)
A
e101	y=0.99x+0.01	1.00	0.98-1.00	0.00-0.02	74.1
e102	y=1.01x-0.01	1.00	1.01-1.02	-0.02-(-0.01)	36.5
e221	y=0.99x	1.00	0.98-1.00	-0.01-0.01	77.6
e226	y=1.04x-0.10	1.00	1.03-1.05	-0.01-(-0.09)	92.7
f353	y=1.01x	1.00	1.00-1.01	-0.01-0.00	77.7
f431	y=0.98x+0.03	1.00	0.97-0.99	0.03-0.04	26.4
f432	y=0.98x+0.05	1.00	0.97-0.99	0.04-0.06	82.0
t224	y=0.99x+0.04	1.00	0.98-1.00	0.04-0.05	74.6

--- Page 8 ---
Highest
Allergen Regression 95% CI 95% CI concentration
Component Equation r2 Slope Intercept tested (kU /L)
A
t227 y=1.05x-0.07 1.00 1.05-1.06 -0.07-(-0.07) 36.5
t240 y=0.99x+0.02 1.00 0.98-0.99 0.01-0.02 30.5
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
i) Traceability:
The IgE calibrators are traceable (via an unbroken chain of calibrations) to the 2nd
International Reference Preparation (IRP) 75/502 of Human Serum
Immunoglobulin E from World Health Organization (WHO).
ii) Kit Stability:
Real-time and Accelerated stability: The stability studies were performed in
accordance with EN 13640 (Stability Testing of In Vitro Diagnostic Reagents) to
demonstrate 24 month unopened shelf-life stability (at recommended storage
temperature of 2-8°C) of the ImmunoCAP Allergen e101, rCan f 1 (Dog); e1,
rCan f 2 (Dog); e221, nCan f 3 (Dog serum albumin); e226, rCan f 5 (Dog); f353,
rGly m 4 PR-10 (Soy); f431, nGly m 5 Beta-conglycinin (Soy); f432, nGly m 6
Glycinin (Soy); t224, rOle e 1 (Olive); t227, nOle e 7 LTP (Olive); t240, rOle e 9
(Olive) by an on-going real time stability study and accelerated stability study.
For real time stability study, three lots of each ImmunoCAP Allergen
Components were stored at recommended storage temperature, 2-8 °C. Two
positive plasma samples and one negative plasma sample were tested at different
occasions according to the ImmunoCAP Specific IgE, Directions for Use, using
Phadia 250. The study is ongoing. For accelerated study, three lots of
ImmunoCAP Allergen Components were stored at 30°C for 8 weeks or 4 weeks
at 40°C. The same lots stored at 2-8 °C was used as reference. They were tested
after 4 and 8 weeks when stored in 30 °C and after 2 and 4 weeks when stored at
40°C, using two positive plasma samples and one negative plasma sample. The
results support the manufacture’s claim of 24 months.
The stability of the calibration curve, real time, and on-board stability of
ImmunoCAP Specific IgE calibrator are detailed in k100999.
d. Detection limit:
The Limit of Blank (LoB) and Limit of Detection (LoD) were determined for each
allergen component on the Phadia 250 in alignment with CLSI EP17-A. The LoB
was based on single determinations of 100 negative samples (blank samples) and was
estimated as the 95% percentile of the distribution. LoD was calculated according to
the equation: LoD = LoB + cß • SD where SD, the standard deviation, was based on
20 determinations of 3 low positive samples, in total 60 determinations. The results
are shown in the table below.
8

[Table 1 on page 8]
					
					Highest
Allergen	Regression		95% CI	95% CI	concentration
Component	Equation	r2	Slope	Intercept	tested (kU /L)
A
t227	y=1.05x-0.07	1.00	1.05-1.06	-0.07-(-0.07)	36.5
t240	y=0.99x+0.02	1.00	0.98-0.99	0.01-0.02	30.5

--- Page 9 ---
Allergen
component LoB LoD
e101 0.006 0.014
e102 0.003 0.010
e221 0.000 0.009
e226 0.021 0.027
f353 0.000 0.010
f431 0.011 0.022
f432 0.000 0.014
t224 0.010 0.018
t227 0.000 0.004
t240 0.007 0.016
e. Analytical specificity:
i) Inhibition studies:
Immunological specificity of the allergen components was verified through
competitive inhibition. The studies were planned in accordance with CLSI
I/LA20-A2. The specific IgE concentration for the positive samples is shown in
the table below.
Allergen
component kU /L
A
e101, rCan f 1 4.9
e102, rCan f 2 4.2
e221, rCan f 3 7.7
e226, rCan f 5 3.3
f353, rGly m 4 6.1
f431, nGly m 5 7.7
f432, nGly m 6 7.7
t224, rOle e 1 4.4
t227, nOle e 7 9.2
t240, nOle e 9 11.1
The allergen solution was serially diluted with buffer to show an overall dose
dependent inhibition. Equal volumes of a positive sample and varying dilutions
of allergen solution (inhibitor) were premixed. The mixture was incubated in a
sample tube at room temperature for 1 hour before being analyzed with the
corresponding ImmunoCAP Allergen Component on ImmunoCAP instrument
according to the manufacturer’s instructions. The testing was performed in
duplicates in one assay run. Mean values were calculated.
The inhibition test was evaluated with inhibition values in %, calculated
according to the formula below:
9

[Table 1 on page 9]
Allergen		
component	LoB	LoD
e101	0.006	0.014
e102	0.003	0.010
e221	0.000	0.009
e226	0.021	0.027
f353	0.000	0.010
f431	0.011	0.022
f432	0.000	0.014
t224	0.010	0.018
t227	0.000	0.004
t240	0.007	0.016

[Table 2 on page 9]
	Allergen				
	component			kU /L
A	
e101, rCan f 1			4.9		
e102, rCan f 2			4.2		
e221, rCan f 3			7.7		
e226, rCan f 5			3.3		
f353, rGly m 4			6.1		
f431, nGly m 5			7.7		
f432, nGly m 6			7.7		
t224, rOle e 1			4.4		
t227, nOle e 7			9.2		
t240, nOle e 9			11.1		

--- Page 10 ---
æ ær-böö
ç ç1-ç ÷÷ ÷´100=i%
è èt-bøø
r = response [RU]
b = background response (100% inhibition) [RU]
t = total response (0% inhibition) [RU]
i = inhibition
Any negative inhibition %-values are shown as 0% inhibition.
The results of the inhibition with the allergen solution and the unrelated inhibitors
indicate that the 10 new allergens contain the immunologically relevant allergen
as shown below:
ImmunoCAP Allergen e101, rCan f 1 (Dog)
The e101, rCan f 1 (Dog) allergen Inhibition study showed that >50% inhibition
was achieved with related inhibitor (e101, rCan f 1, Dog allergen) at a final
inhibitor concentration of 5 µg/mL. The inhibition studies using four unrelated
inhibitors, including three from unrelated groups (r Hev b 6.01, Latex; rBet v 2,
Birch; and rPru p 1, Peach) and one from the related/same group (rCan f5, Dog)
did not show any significant inhibition. The inhibition studies indicate that the
ImmunoCAP Allergen e101, rCan f 1 (Dog) solid phase contains the
immunologically relevant allergen.
ImmunoCAP Allergen e102, rCan f 2 (Dog)
The e102, rCan f 2 (Dog) allergen Inhibition study showed that >50% inhibition
was achieved with related inhibitor (e102, rCan f 2, Dog allergen) at a final
inhibitor concentration of 5 µg/mL. The inhibition studies using four unrelated
inhibitors, including three from unrelated groups (rHev b 6.01, Latex; rBet v 2,
Birch; and rPen a 1, Shrimp) and one from the related/same group (rCan f5, Dog)
did not show any significant inhibition. The inhibition studies indicate that the
ImmunoCAP Allergen e102, rCan f 2 (Dog) solid phase contains the
immunologically relevant allergen.
ImmunoCAP Allergen e221, nCan f 3 (Dog serum albumin)
The e221, rCan f 3 (Dog serum albumin ) allergen Inhibition study showed that
>50% inhibition was achieved with related inhibitor (e221, rCan f 3, Dog serum
albumin allergen) at a final inhibitor concentration of 5 µg/mL. The inhibition
studies using four unrelated inhibitors, including three from unrelated groups
(rPru p 1, Peach; rPhl 5b, Timothy; and rBet v 2, Birch) and one from the
related/same group (rCan f5, Dog) did not show any significant inhibition. The
inhibition studies indicate that the ImmunoCAP Allergen e221, nCan f 3 (Dog
serum albumin) solid phase contains the immunologically relevant allergen.
ImmunoCAP Allergen e226, rCan f 5 (Dog)
The e226, rCan f 5 (Dog) allergen Inhibition study showed that >50% inhibition
was achieved with related inhibitor (e226, rCan f 5 (Dog) allergen) at a final
10

--- Page 11 ---
inhibitor concentration of 5 µg/mL. The inhibition studies using four unrelated
inhibitors, including three from unrelated groups (nCyn d 1, Bermuda grass; rBet
v 1, Birch; and rDer p 2, House dust mite) and one from the related/same group
(rCan f3, Dog) did not show any significant inhibition. The inhibition studies
indicate that the ImmunoCAP Allergen e226, rCan f 5 (Dog) solid phase contains
the immunologically relevant allergen.
ImmunoCAP Allergen f353, rGly m 4 PR-10 (Soy)
The f353, rGly m 4 PR-10 (Soy) allergen Inhibition study showed that 94%
inhibition was achieved with related inhibitor (f353, rGly m 4 PR-10 (Soy)) at a
final inhibitor concentration of 500 µg/mL. The inhibition studies using five
unrelated inhibitors, including three from unrelated groups (rPhl p 7, Timothy;
rFel d 1, Cat; and r Hev b 6.01, Latex) and two from the related/same group: f346
( Abalone) and f233 nGal d 1 (Egg) did not show any significant inhibition. The
inhibition studies indicate that the ImmunoCAP Allergen f353, rGly m 4 PR-10
(Soy) solid phase contains the immunologically relevant allergen.
ImmunoCAP Allergen f431, nGly m 5 Beta-conglycinin (Soy)
The f431, nGly m 5 Beta-conglycinin (Soy) allergen Inhibition study showed that
>50% inhibition was achieved with related inhibitor (f431, nGly m 5 Beta-
conglycinin (Soy) at a final inhibitor concentration of 5 µg/mL. The inhibition
studies using four unrelated inhibitors, including three from unrelated groups
(rFel d 1, Cat; rPhl p1, Timothy; and nGal d 4, Egg) and one from the
related/same group (rGly m4, Soy) did not show any significant inhibition. The
inhibition studies indicate that the ImmunoCAP Allergen f431, nGly m 5 Beta-
conglycinin (Soy) solid phase contains the immunologically relevant allergen.
ImmunoCAP Allergen f432, nGly m 6 Glycinin (Soy)
The f432, nGly m 6 Glycinin (Soy) allergen Inhibition study showed that 86%
inhibition was achieved with related inhibitor (f432, nGly m 6 Glycinin (Soy)) at
a final inhibitor concentration of 500 µg/mL. The inhibition studies using five
unrelated inhibitors, including three from unrelated groups (rFel d 1, Cat; rPhl p1,
Timothy; and d74, Storage mite) and two from the related/same group: f346
(Abalone) and f233 nGal d 1 (Egg) did not show any significant inhibition. The
inhibition studies indicate that the ImmunoCAP Allergen f432, nGly m 6
Glycinin (Soy) solid phase contains the immunologically relevant allergen.
ImmunoCAP Allergen t224, rOle e 1 (Olive)
The t224, rOle e 1 (Olive) allergen Inhibition study showed that >50% inhibition
was achieved with related inhibitor (t224, rOle e 1 (Olive) allergen) at a final
inhibitor concentration of 5 µg/mL. The inhibition studies using four unrelated
inhibitors, including three from unrelated groups (rCan f 1, Dog; nCyn d 1,
Bermuda grass; and rDer p 2, House dust mite) and one from the related/same
group (rOle e 9, Olive) did not show any significant inhibition. The inhibition
studies indicate that the ImmunoCAP Allergen t224, rOle e 1 (Olive) solid phase
contains the immunologically relevant allergen.
ImmunoCAP Allergen t227, nOle e 7 LTP (Olive)
The t227, nOle e 7 LTP (Olive) allergen Inhibition study showed that >50%
11

--- Page 12 ---
inhibition was achieved with related inhibitor (t227, nOle e 7 LTP (Olive)
allergen) at a final inhibitor concentration of 5 µg/mL. The inhibition studies
using four unrelated inhibitors, including three from unrelated groups (nGal d 3,
Egg, r Hev b 6.01, Latex, and rDer p 2, House dust mite) and one from the
related/same group (rOle e 1, Olive) did not show any significant inhibition. The
inhibition studies indicate that the ImmunoCAP Allergen t227, nOle e 7 LTP
(Olive) solid phase contains the immunologically relevant allergen.
ImmunoCAP Allergen t240, rOle e 9 (Olive)
The t240, rOle e 9 (Olive) allergen Inhibition study showed that >50% inhibition
was achieved with related inhibitor (t240, rOle e 9 (Olive) allergen) at a final
inhibitor concentration of 5 µg/mL. The inhibition studies using four unrelated
inhibitors, including three from unrelated groups (nGal d 3, Egg; r Hev b 6.01,
Latex; and rDer p 2, House dust mite) and one from the related/same group (rOle
e 1, Olive) did not show any significant inhibition. The inhibition studies indicate
that the ImmunoCAP Allergen t240, rOle e 9 (Olive) solid phase contains the
immunologically relevant allergen.
ii) Interference:
a) Endogenous Substance Interference:
In order to show that icteric, hemolytic or lipemic samples do not adversely
affects the results in ImmunoCAP Specific IgE assay using representative
allergens, Bilirubin C [final concentration (fc) 20 mg/dL], Bilirubin F (fc 19
mg/dL), Hemoglobin (fc 489 mg/dL) and Chyle (fc 1,440 Formazine
Turbidity Units) were spiked into 2 samples per allergen. The allergens tested
were e228 rFel d 4, Cat; f351 rPen a 1,Tropomyosin Shrimp; f354 rBer e 1,
Brazil nut; f420 rPru p 3, LTP Peach; and w231 nArt v 1, Mugwort. The
design of the studies was in general alignment with CLSI EP7-A2 Guideline.
The results demonstrate that icteric, hemolytic or lipemic samples do not
adversely affects the results in ImmunoCAP Specific IgE.
b) Exogenous Substance Interference:
Two literature references were provided supporting that commonly prescribed
"allergy medications" do not interfere with ImmunoCAP Specific IgE. The
references included (i) Robert G. Hamilton, Accuracy of US Food and Drug
Administration-cleared IgE antibody assays in the presence of anti-IgE
(omalizumab), J. Allergy Clin. Immunol. 2006; 759-766, and (ii) Linda Cox et
al., Pearls and pitfalls of allergy diagnostic testing: report from the American
College of Allergy, Asthma and Immunology/American Academy of Allergy,
Asthma and Immunology Specific IgE Test Task Force, Annals of Allergy,
Asthma & Immunology, 2008; 101:580-592.
f. Assay cut-off:
Limit of Quantitation for ImmunoCAP Specific IgE is 0.1 kU /L. All results >0.1 kU
A
//L are interpreted as being analytically positive.
A
12

--- Page 13 ---
2. Comparison studies:
a. Method comparison with predicate device:
Refer to clinical studies.
b. Matrix comparison:
The "Proof of Principle" study that different matrix samples (heparin plasma, EDTA
plasma and serum) are interchangeable for ImmunoCAP Allergen Components was
provided in k101251. Serum, sodium heparin plasma, and EDTA plasma samples
were collected from four patients with clinical history of known specific allergies and
four nonatopic patients. The samples contained specific IgE antibodies for one or
more of the allergen components tested. ·All sample matrices (heparin plasma, EDTA
plasma and serum) from each patient were tested with ImmunoCAP Allergen
Components in 2 replicates in one assay run. Mean concentration values for each
sample matrix were calculated. Mean logarithmic ratios for 17 results were -0.022
(Plasma heparin/Serum) and 0.054 (Plasma EDTA/Serum). The results from the
study show that samples of different matrices (heparin plasma, EDTA plasma and
serum) are interchangeable for ImmunoCAP Allergen Components.
3. Clinical studies:
a. Clinical Sensitivity and specificity:
The performance of the ten new individual allergen components was compared to a
clinical diagnosis of allergy. The objective of this study was, (i) to show the linkage
between specific IgE antibodies to ImmunoCAP Allergen Component and the
corresponding extract based ImmunoCAP Allergen, using clinical samples, and (ii) to
demonstrate that samples from healthy, non-atopic donors with no reported clinical
reaction to the allergen have undetectable or very low levels of specific IgE to the
individual ImmunoCAP Allergen Component. Fifty one clinical serum samples from
individuals with a clinical history of allergy-like symptoms upon exposure to the
allergen, as diagnosed by a physician were used in the study. Information about
clinical symptoms and manifestations was available for all clinical samples. 100
negative samples (<0.35 kU /L) from healthy non-atopic donors were also tested.
A
ImmunoCAP Allergen e101, rCan f 1 (Dog)
Clinical Diagnosis
Atopic Non-atopic Total
Positive 69 0 69
Allergen e101,
Negative 0 100 100
rCan f 1 (Dog)
Total 69 100 169
Sensitivity =100% (69/69) (95% CI: 94.8 - 100%)
Specificity =100% (100/100) (95% CI: 96.4 - 100%)
13

[Table 1 on page 13]
							Clinical Diagnosis							
							Atopic			Non-atopic			Total	
				Positive		69			0			69		
	Allergen e101,													
				Negative		0			100			100		
	rCan f 1 (Dog)													
				Total		69			100			169		
														

--- Page 14 ---
ImmunoCAP Allergen e102, rCan f 2 (Dog)
Clinical Diagnosis
Atopic Non-atopic Total
Positive 40 0 40
Allergen e102,
Negative 0 100 100
rCan f 2 (Dog)
Total 40 100 140
Sensitivity =100% (40/40) (95% CI: 91.2 - 100%)
Specificity =100% (100/100) (95% CI: 96.4 - 100%)
ImmunoCAP Allergen e221, nCan f 3 (Dog serum albumin)
Clinical Diagnosis
Atopic Non-atopic Total
Allergen e221, Positive 41 0 41
nCan f 3 (Dog Negative 0 100 100
serum albumin) Total 41 100 141
Sensitivity =100% (41/41) (95% CI: 91.4 - 100%)
Specificity =100% (100/100) (95% CI: 96.4 - 100%)
ImmunoCAP Allergen e226, rCan f 5 (Dog)
Clinical Diagnosis
Atopic Non-atopic Total
Positive 40 0 40
Allergen e226,
Negative 0 100 100
rCan f 5 (Dog)
Total 40 100 140
Sensitivity =100% (40/40) (95% CI: 91.2 - 100%)
Specificity =100% (100/100) (95% CI: 96.4 - 100%)
ImmunoCAP Allergen f353, rGly m 4 PR-10 (Soy)
Clinical Diagnosis
Atopic Non-atopic Total
Allergen f353, Positive 30 0 30
rGly m 4 PR-10 Negative 0 100 100
(Soy) Total 30 100 130
Sensitivity =100% (30/30) (95% CI: 88.4 - 100%)
Specificity =100% (100/100) (95% CI: 96.4 - 100.0%)
14

[Table 1 on page 14]
						Clinical Diagnosis				
						Atopic			Non-atopic	Total
			Positive		40			0		40
Allergen e102,
rCan f 2 (Dog)										
			Negative		0			100		100
			Total		40			100		140
										

[Table 2 on page 14]
						Clinical Diagnosis				
						Atopic			Non-atopic	Total
Allergen e221,
nCan f 3 (Dog
serum albumin)			Positive		41			0		41
			Negative		0			100		100
			Total		41			100		141

[Table 3 on page 14]
						Clinical Diagnosis				
						Atopic			Non-atopic	Total
			Positive		40			0		40
Allergen e226,
rCan f 5 (Dog)										
			Negative		0			100		100
			Total		40			100		140
										

[Table 4 on page 14]
						Clinical Diagnosis				
						Atopic			Non-atopic	Total
Allergen f353,
rGly m 4 PR-10
(Soy)			Positive		30			0		30
			Negative		0			100		100
			Total		30			100		130

--- Page 15 ---
ImmunoCAP Allergen f431, nGly m 5 Beta-conglycinin (Soy)
Clinical Diagnosis
Atopic Non-atopic Total
Allergen f431, Positive 31 0 31
nGly m 5 Beta- Negative 0 100 100
conglycinin
Total 31 100 131
(Soy)
Sensitivity =100% (31/31) (95% CI: 88.8 - 100%)
Specificity =100% (100/100) (95% CI: 96.4 - 100%)
ImmunoCAP Allergen f432, nGly m 6 Glycinin (Soy)
Clinical Diagnosis
Atopic Non-atopic Total
Allergen f432, Positive 35 0 35
nGly m 6 Negative 0 100 100
Glycinin (Soy) Total 35 100 135
Sensitivity =100% (35/35) (95% CI: 90.0 - 100%)
Specificity =100% (100/100) (95% CI: 96.4 - 100%)
ImmunoCAP Allergen t224, rOle e 1 (Olive)
Clinical Diagnosis
Atopic Non-atopic Total
Positive 34 0 34
Allergen t224,
Negative 0 100 100
rOle e 1 (Olive)
Total 34 100 134
Sensitivity =100% (34/34) (95% CI: 89.7 - 100%)
Specificity =100% (100/100) (95% CI: 96.4-100.0%)
ImmunoCAP Allergen t227, nOle e 7 LTP (Olive)
Clinical Diagnosis
Atopic Non-atopic Total
Allergen t227, Positive 31 0 31
nOle e 7 LTP Negative 0 100 100
(Olive) Total 31 100 131
Sensitivity =100% (31/31) (95% CI: 88.8 - 100%)
Specificity =100% (100/100) (95% CI: 96.4 - 100%)
15

[Table 1 on page 15]
							Clinical Diagnosis							
							Atopic			Non-atopic			Total	
	Allergen f431,			Positive		31			0			31		
	nGly m 5 Beta-			Negative		0			100			100		
	conglycinin					31			100			131		
				Total										
	(Soy)													
														

[Table 2 on page 15]
							Clinical Diagnosis							
							Atopic			Non-atopic			Total	
	Allergen f432,			Positive		35			0			35		
	nGly m 6			Negative		0			100			100		
	Glycinin (Soy)			Total		35			100			135		

[Table 3 on page 15]
							Clinical Diagnosis							
							Atopic			Non-atopic			Total	
				Positive		34			0			34		
	Allergen t224,													
				Negative		0			100			100		
	rOle e 1 (Olive)													
				Total		34			100			134		
														

[Table 4 on page 15]
							Clinical Diagnosis							
							Atopic			Non-atopic			Total	
	Allergen t227,			Positive		31			0			31		
	nOle e 7 LTP			Negative		0			100			100		
	(Olive)			Total		31			100			131		

--- Page 16 ---
ImmunoCAP Allergen t240, rOle e 9 (Olive)
Clinical Diagnosis
Atopic Non-atopic Total
Positive 36 0 36
Allergen t240,
Negative 0 100 100
rOle e 9 (Olive)
Total 36 100 136
Sensitivity =100% (36/36) (95% CI: 90.3 - 100%)
Specificity =100% (100/100) (95% CI: 96.4 - 100%)
All negative samples showed undetectable level (<0.1 kU /L) of allergen specific
A
IgE. Studies described above were performed on the Phadia 1000 instrument system.
b. Other clinical supportive data (when a. is not applicable):
Not applicable
4. Clinical cut-off:
Not applicable
5. Expected values/Reference range:
The expected value is negative (< 0.35 kU /L) for a specific allergen in a non-allergic
A
person. The manufacturer recommends a cut-off of 0.35 kU /L. Each laboratory should
A
establish its own expected range of values.
N. Instrument Name:
Phadia 100, Phadia 250, Phadia 1000, Phadia 2500 and Phadia 5000 instrument system.
O. System Descriptions:
1. Software:
FDA has reviewed applicant’s Hazard Analysis and software development processes for
this line of product types:
Yes __X__ or No ____
P. Other Supportive Instrument Performance Characteristics Data Not Covered In The
“Performance Characteristics” Section above:
Refer to k101251 for assay Precision study of ImmunoCAP Allergen Components on Phadia
100, Phadia 250 and Phadia 1000.
16

[Table 1 on page 16]
							Clinical Diagnosis							
							Atopic			Non-atopic			Total	
				Positive		36			0			36		
	Allergen t240,													
				Negative		0			100			100		
	rOle e 9 (Olive)													
				Total		36			100			136		
														

--- Page 17 ---
Q. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
R. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.
17